Multinationals, Patients Benefit From New Approvals As China Speeds Reviews
Executive Summary
The China FDA’s new priority reviews and faster approval procedures for innovative drugs are beginning to bear fruit, with multinationals and patients among the first beneficiaries from recent clearances from two novel cancer drugs in this large emerging market.